ClinicalTrials.gg
TerminatedNCT02956122Updated Jan 13, 2021Results posted

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

A Phase 2/3 interventional study of GLASSIA and methylprednisolone or equivalent steroid in Graft Versus Host Disease, sponsored by Baxalta now part of Shire. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-13.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
The decision to discontinue the study was based on business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
357th of 389
1 · median 30
Started
2017
with 16 others
Phase 2/3
8 of 454
none open now
Registered
316th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 357th largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2017, is one of 8 in phase 2/3, and was the 316th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥18 years at the time of screening
  2. Recipient of an hematopoietic stem cell transplantation ()
  3. The disease indication for which the participant required HSCT must be in remission
  4. Newly diagnosed acute (GvHD), including lower Gastrointestinal (GI) involvement (modified International Bone Marrow Transplant Registry [IBMTR] Severity Stage 1 to 4 [>500 mL diarrhea/day]), with or without other organ system involvement.
  5. Willing to undergo or must have had a lower GI within 7 days of to confirm GI GvHD. Biopsy results are not needed to initiate treatment; however, if biopsy results are not consistent with aGvHD, treatment with GLASSIA will be discontinued.
  6. Participants must be receiving systemic . Treatment with methylprednisolone/systemic steroids must have been initiated within 72 hours prior to the first dose of study treatment after enrollment
  7. Evidence of myeloid engraftment ( ≥0.5 x 10\^9/L)
  8. Lower GI GvHD manifested by diarrhea must have other causes of diarrhea ruled out (eg, negative for Clostridium difficile or cytomegalovirus [CMV] infection or oral magnesium administration)
  9. Performance Score ≥50%
  10. If female of , participant presents with a negative blood pregnancy test
  11. Females of childbearing potential with a fertile male sexual partner must agree to employ adequate for the duration of the study.
  12. Males must use adequate contraception and must not donate sperm for the duration of the study.
  13. Participant is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  1. Participant with manifestations of chronic GvHD
  2. Participant with acute/chronic GvHD overlap syndrome
  3. Participant whose GvHD developed after donor lymphocyte infusion
  4. Participant with myocardial infarction within 6 months prior to enrollment or Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to the first dose of study treatment, any (ECG) abnormality at screening must be documented by the investigator as not medically relevant
  5. Participant with evidence of recurrent
  6. Participant with veno-occlusive disease (ie, sinusoidal obstruction syndrome)
  7. Participant receiving GvHD treatment other than continued prophylaxis (eg, cyclosporine and/or mycophenolate mofetil, etc) or therapy. In addition, a participant who received the first dose of corticosteroid therapy for acute GvHD with lower GI involvement more than 72 hours before the first dose of study treatment is not eligible for the study
  8. Participant with severe sepsis involving at least 1 organ failure
  9. Participant who is seropositive or positive in the nucleic acid test for (HIV)
  10. Participant with active or C
  11. Participant has participated in another clinical study involving an product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  12. If female, participant is pregnant or lactating at the time of enrollment, or has plans to become pregnant during the study
  13. Participant with a serious medical or psychiatric illness likely to interfere with participation in the study
  14. Participant is a family member or employee of the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Study Part 1 - All Participants - GLASSIA

    Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

    Biological: GLASSIA · Drug: methylprednisolone or equivalent steroid

  • Experimental
    Study Part 2 - GLASSIA

    Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

    Biological: GLASSIA · Drug: methylprednisolone or equivalent steroid

  • Placebo comparator
    Study Part 2 - Albumin (Control)

    Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

    Drug: methylprednisolone or equivalent steroid · Biological: Albumin

Interventions

  • BiologicalGLASSIA

    GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

    Also known as: as alpha-1 antitrypsin, A1PI, alpha-1 proteinase inhibitor

  • Drugmethylprednisolone or equivalent steroid

    The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

  • BiologicalAlbumin

    The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).

    Also known as: Human Albumin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Overall Response (OR) At Day 28

    OR was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage and GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.

    Time frame: Day 28

Secondary outcomes

  1. Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28

    GI response was defined as complete response (CR) + partial response (PR), defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to less than or equal to (\<=) 50% of required calories; and reduction of stool volume by greater than or equal to (\>=) 50%, without ileus.

    Time frame: Day 28

  2. Percentage of Participants Achieving Overall Response at Day 56

    Overall response was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.

    Time frame: Day 56

  3. Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180

    Grading of GvHD was performed by the investigator according to the modified International Bone Marrow Transplant Registry (IBMTR) grading system which classifies the degree of involvement of each organ system by stage on a scale of 0 to 4. The degree of skin involvement was staged depending upon degree and severity of the lesions: Stage 1: Maculopapular rash over less than (\<) 25% of body area, Stage 2: Maculopapular rash over 25 to 50% of body area, Stage 3: Generalized erythroderma, Stage 4: Generalized erythroderma with bullous formation. Degree of GI involvement was staged based on severity of diarrhoea: Stage 1: 500 to 1000 mL/day,Stage 2: 1000 to 1500 mL/day, Stage 3: 1500 to 2000 mL/day, Stage 4: greater than (\>) 2000 mL/day OR pain OR ileus. Degree of liver involvement was staged based upon serum total bilirubin level as follows: Stage 1: 2 to 3 mg/dL, Stage 2: 3 to 6 mg/dL, Stage 3: 6 to 15 mg/dL, Stage 4: \>15 mg/dL.

    Time frame: Days 28, 56 and 180

  4. Incidence of Chronic Graft-versus-host Disease (GvHD)

    Incidence of chronic GvHD at Days 180 and 365 was reported.

    Time frame: Days 180 and 365

  5. Duration of Overall Response (OR)

    OR was defined as GvHD CR + PR, defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs. Duration of OR was not assessed due to the termination of the study.

    Time frame: Baseline up to Day 365

  6. Duration of Gastrointestinal (GI) Response

    GI response was defined as CR + PR, defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to \<= 50% of required calories; and reduction of stool volume by \>= 50%, without ileus. Duration of GI response was not assessed due to the termination of the study.

    Time frame: Baseline up to Day 365

  7. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Days 100, 180 and 365

  8. Transplant-related Mortality

    Transplant-related mortality was determined by the investigator (any deaths considered related to the transplant).

    Time frame: Days 28, 56, 100 and 180

  9. Failure-free Survival - Percentage of Participants With an Event

    Failure-free survival was defined as the absence of all of the following criteria: Need for second-line treatment for acute GvHD, Non-relapse mortality (death during continuous complete remission) and recurrent malignancy.

    Time frame: Days 100 and 180

  10. Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event

    GVHD-free survival was defined as being alive without previous onset of acute GVHD or chronic GVHD requiring immunosuppressive therapy.

    Time frame: Days 28, 56, 100, 180 and 365

  11. Infection-related Mortality - Percentage of Participants With an Event

    Infection-related mortality was determined by the investigator (any deaths considered related to infection \[including infections related to hematopoietic stem cell transplant {HSCT}\]).

    Time frame: Days 28, 56, 100 and 180

  12. Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event

    Graft-versus-host disease (GvHD)-related mortality was determined by the investigator (any deaths considered related to GvHD).

    Time frame: Days 28, 56, 100 and 180

  13. All-cause Mortality - Percentage of Participants With an Event

    All-cause mortality was defined as the time from HSCT to death due to any cause.

    Time frame: Days 28, 56, 100 and 180

  14. Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs

    An AE was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. An SAE was defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome was fatal/results in death, life-threatening, required inpatient hospitalization or resulted in prolongation of an existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From start of study drug administration up to 371 days

  15. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Clinical laboratory assessments such as hematology, clinical chemistry, lipid and coagulation panels and urinalysis were performed.

    Time frame: Baseline up to Day 56

  16. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included body temperature, respiratory rate, pulse rate and systolic and diastolic blood pressure.

    Time frame: Baseline up to Day 56

  17. Number of Participants With Recurrence of Primary Malignancies

    Incidence of recurrence of primary malignancies was reported.

    Time frame: Baseline up to Day 365

  18. Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity

    AUC of GLASSIA was reported.

    Time frame: Day 1: through 48 hours; Day 13: through 48 hours; Day 22 and Day 50: through approximately 168 hours

  19. Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA

    AUC(0-t) of GLASSIA was reported.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  20. Systemic Clearance at Steady State (CLss) of GLASSIA

    CLss of GLASSIA was reported.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  21. Maximum Observed Plasma Concentration (Cmax) of GLASSIA

    Cmax of GLASSIA was reported.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  22. Apparent Volume of Distribution at Steady State (Vss) of GLASSIA

    Vss of GLASSIA was reported.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  23. Apparent Terminal Half-life (t1/2) of GLASSIA

    Apparent terminal half-life (hour), determined as ln2/lambda-z. lambda-z is the apparent terminal rate constant (one per hour), determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points will be used for determination. t1/2 of GLASSIA was reported.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  24. Mean Residence Time (MRT) of GLASSIA

    MRT of GLASSIA was not calculated.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

  25. Trough Plasma Concentration at Steady State (Ctrough) of GLASSIA

    Ctrough of GLASSIA was not assessed due to the termination of the study.

    Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

07

Results

Posted Apr 24, 2019

Participant flow

Study was conducted between 26 April 2017 (first participant first visit) and 03 May 2018 (last participant last visit).

Participant flow — Overall Study
MilestoneGLASSIA
Started1
Completed1
Not completed0

Outcome measures

PrimaryPercentage of Participants Achieving Overall Response (OR) At Day 28

OR was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage and GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Overall Response (OR) At Day 28
Percentage of participantsGLASSIA
Percentage of Participants Achieving Overall Response (OR) At Day 28100
SecondaryPercentage of Participants Achieving Gastrointestinal (GI) Response at Day 28

GI response was defined as complete response (CR) + partial response (PR), defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to less than or equal to (\<=) 50% of required calories; and reduction of stool volume by greater than or equal to (\>=) 50%, without ileus.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28
Percentage of participantsGLASSIA
Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28100
SecondaryPercentage of Participants Achieving Overall Response at Day 56

Overall response was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.

Time frame:
Day 56
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Overall Response at Day 56
Percentage of participantsGLASSIA
Percentage of Participants Achieving Overall Response at Day 56100
SecondaryAcute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180

Grading of GvHD was performed by the investigator according to the modified International Bone Marrow Transplant Registry (IBMTR) grading system which classifies the degree of involvement of each organ system by stage on a scale of 0 to 4. The degree of skin involvement was staged depending upon degree and severity of the lesions: Stage 1: Maculopapular rash over less than (\<) 25% of body area, Stage 2: Maculopapular rash over 25 to 50% of body area, Stage 3: Generalized erythroderma, Stage 4: Generalized erythroderma with bullous formation. Degree of GI involvement was staged based on severity of diarrhoea: Stage 1: 500 to 1000 mL/day,Stage 2: 1000 to 1500 mL/day, Stage 3: 1500 to 2000 mL/day, Stage 4: greater than (\>) 2000 mL/day OR pain OR ileus. Degree of liver involvement was staged based upon serum total bilirubin level as follows: Stage 1: 2 to 3 mg/dL, Stage 2: 3 to 6 mg/dL, Stage 3: 6 to 15 mg/dL, Stage 4: \>15 mg/dL.

Time frame:
Days 28, 56 and 180
Reported as:
Count of participants · Participants
Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180
ParticipantsGLASSIA
Day 28: Degree of skin Involvement — Stage 01
Day 28: Degree of skin Involvement — Stage 10
Day 28: Degree of skin Involvement — Stage 20
Day 28: Degree of skin Involvement — Stage 30
Day 28: Degree of skin Involvement — Stage 40
Day 28: Degree of GI Involvement — Stage 01
Day 28: Degree of GI Involvement — Stage 10
Day 28: Degree of GI Involvement — Stage 20
Day 28: Degree of GI Involvement — Stage 30
Day 28: Degree of GI Involvement — Stage 40
Day 28: Degree of liver Involvement — Stage 01
Day 28: Degree of liver Involvement — Stage 10
Day 28: Degree of liver Involvement — Stage 20
Day 28: Degree of liver Involvement — Stage 30
Day 28: Degree of liver Involvement — Stage 40
Day 56: Degree of skin Involvement — Stage 01
Day 56: Degree of skin Involvement — Stage 10
Day 56: Degree of skin Involvement — Stage 20
Day 56: Degree of skin Involvement — Stage 30
Day 56: Degree of skin Involvement — Stage 40
Day 56: Degree of GI Involvement — Stage 01
Day 56: Degree of GI Involvement — Stage 10
Day 56: Degree of GI Involvement — Stage 20
Day 56: Degree of GI Involvement — Stage 30
Day 56: Degree of GI Involvement — Stage 40
Day 56: Degree of liver Involvement — Stage 01
Day 56: Degree of liver Involvement — Stage 10
Day 56: Degree of liver Involvement — Stage 20
Day 56: Degree of liver Involvement — Stage 30
Day 56: Degree of liver Involvement — Stage 40
Day 180: Degree of skin Involvement — Stage 01
Day 180: Degree of skin Involvement — Stage 10
Day 180: Degree of skin Involvement — Stage 20
Day 180: Degree of skin Involvement — Stage 30
Day 180: Degree of skin Involvement — Stage 40
Day 180: Degree of GI Involvement — Stage 01
Day 180: Degree of GI Involvement — Stage 10
Day 180: Degree of GI Involvement — Stage 20
Day 180: Degree of GI Involvement — Stage 30
Day 180: Degree of GI Involvement — Stage 40
Day 180: Degree of liver Involvement — Stage 01
Day 180: Degree of liver Involvement — Stage 10
Day 180: Degree of liver Involvement — Stage 20
Day 180: Degree of liver Involvement — Stage 30
Day 180: Degree of liver Involvement — Stage 40
SecondaryIncidence of Chronic Graft-versus-host Disease (GvHD)

Incidence of chronic GvHD at Days 180 and 365 was reported.

Time frame:
Days 180 and 365
Reported as:
Number · Participants
Incidence of Chronic Graft-versus-host Disease (GvHD)
ParticipantsGLASSIA
Day 1800
Day 3650
SecondaryDuration of Overall Response (OR)

OR was defined as GvHD CR + PR, defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs. Duration of OR was not assessed due to the termination of the study.

Time frame:
Baseline up to Day 365

No measurements were reported for this outcome.

SecondaryDuration of Gastrointestinal (GI) Response

GI response was defined as CR + PR, defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to \<= 50% of required calories; and reduction of stool volume by \>= 50%, without ileus. Duration of GI response was not assessed due to the termination of the study.

Time frame:
Baseline up to Day 365

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of randomization to the date of death due to any cause.

Time frame:
Days 100, 180 and 365
Reported as:
Number · Percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 100NA
Day 180NA
Day 365NA
SecondaryTransplant-related Mortality

Transplant-related mortality was determined by the investigator (any deaths considered related to the transplant).

Time frame:
Days 28, 56, 100 and 180
Reported as:
Count of participants · Participants
Transplant-related Mortality
ParticipantsGLASSIA
Day 280
Day 560
Day 1000
Day 1800
SecondaryFailure-free Survival - Percentage of Participants With an Event

Failure-free survival was defined as the absence of all of the following criteria: Need for second-line treatment for acute GvHD, Non-relapse mortality (death during continuous complete remission) and recurrent malignancy.

Time frame:
Days 100 and 180
Reported as:
Number · Percentage of participants
Failure-free Survival - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 100100
Day 180100
SecondaryGraft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event

GVHD-free survival was defined as being alive without previous onset of acute GVHD or chronic GVHD requiring immunosuppressive therapy.

Time frame:
Days 28, 56, 100, 180 and 365
Reported as:
Number · Percentage of participants
Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 28100
Day 56100
Day 100100
Day 180100
Day 365100
SecondaryInfection-related Mortality - Percentage of Participants With an Event

Infection-related mortality was determined by the investigator (any deaths considered related to infection \[including infections related to hematopoietic stem cell transplant {HSCT}\]).

Time frame:
Days 28, 56, 100 and 180
Reported as:
Number · Percentage of participants
Infection-related Mortality - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 280
Day 560
Day 1000
Day1800
SecondaryGraft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event

Graft-versus-host disease (GvHD)-related mortality was determined by the investigator (any deaths considered related to GvHD).

Time frame:
Days 28, 56, 100 and 180
Reported as:
Number · Percentage of participants
Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 280
Day 560
Day 1000
Day 1800
SecondaryAll-cause Mortality - Percentage of Participants With an Event

All-cause mortality was defined as the time from HSCT to death due to any cause.

Time frame:
Days 28, 56, 100 and 180
Reported as:
Number · Percentage of participants
All-cause Mortality - Percentage of Participants With an Event
Percentage of participantsGLASSIA
Day 280
Day 560
Day 1000
Day1800
SecondaryNumber of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs

An AE was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. An SAE was defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome was fatal/results in death, life-threatening, required inpatient hospitalization or resulted in prolongation of an existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From start of study drug administration up to 371 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs
ParticipantsGLASSIA
Any Adverse Event1
Treatment-related AEs0
Serious adverse Events (SAEs)0
Treatment-related SAEs0
Temporally-associated AEs0
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Clinical laboratory assessments such as hematology, clinical chemistry, lipid and coagulation panels and urinalysis were performed.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsGLASSIA
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments0
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs included body temperature, respiratory rate, pulse rate and systolic and diastolic blood pressure.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsGLASSIA
Number of Participants With Clinically Significant Changes in Vital Signs0
SecondaryNumber of Participants With Recurrence of Primary Malignancies

Incidence of recurrence of primary malignancies was reported.

Time frame:
Baseline up to Day 365
Reported as:
Count of participants · Participants
Number of Participants With Recurrence of Primary Malignancies
ParticipantsGLASSIA
Number of Participants With Recurrence of Primary Malignancies0
SecondaryArea Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity

AUC of GLASSIA was reported.

Time frame:
Day 1: through 48 hours; Day 13: through 48 hours; Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · Hour*milligrams per deciliter (h*mg/dL)
Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity
Hour*milligrams per deciliter (h*mg/dL)GLASSIA: Day 1: 90 mg/kgGLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity6150043500126000117000
SecondaryArea Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA

AUC(0-t) of GLASSIA was reported.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · h*mg/dL
Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA
h*mg/dLGLASSIA: Day 1: 90 mg/kgGLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA16300110004040033400
SecondarySystemic Clearance at Steady State (CLss) of GLASSIA

CLss of GLASSIA was reported.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · Deciliters per hour (dL/h)
Systemic Clearance at Steady State (CLss) of GLASSIA
Deciliters per hour (dL/h)GLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Systemic Clearance at Steady State (CLss) of GLASSIA0.2970.2860.260
SecondaryMaximum Observed Plasma Concentration (Cmax) of GLASSIA

Cmax of GLASSIA was reported.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · Milligrams per deciliter (mg/dl)
Maximum Observed Plasma Concentration (Cmax) of GLASSIA
Milligrams per deciliter (mg/dl)GLASSIA: Day 1: 90 mg/kgGLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Maximum Observed Plasma Concentration (Cmax) of GLASSIA339262390409
SecondaryApparent Volume of Distribution at Steady State (Vss) of GLASSIA

Vss of GLASSIA was reported.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · Deciliter (dL)
Apparent Volume of Distribution at Steady State (Vss) of GLASSIA
Deciliter (dL)GLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Apparent Volume of Distribution at Steady State (Vss) of GLASSIA50.912391.1
SecondaryApparent Terminal Half-life (t1/2) of GLASSIA

Apparent terminal half-life (hour), determined as ln2/lambda-z. lambda-z is the apparent terminal rate constant (one per hour), determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points will be used for determination. t1/2 of GLASSIA was reported.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Reported as:
Number · Hour (h)
Apparent Terminal Half-life (t1/2) of GLASSIA
Hour (h)GLASSIA: Day 1: 90 mg/kgGLASSIA: Day 13: 30 mg/kgGLASSIA: Day 22: 120 mg/kgGLASSIA: Day 50: 120 mg/kg
Apparent Terminal Half-life (t1/2) of GLASSIA152117317247
SecondaryMean Residence Time (MRT) of GLASSIA

MRT of GLASSIA was not calculated.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

No measurements were reported for this outcome.

SecondaryTrough Plasma Concentration at Steady State (Ctrough) of GLASSIA

Ctrough of GLASSIA was not assessed due to the termination of the study.

Time frame:
Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours

No measurements were reported for this outcome.

Adverse events

Collected over From the start of drug administration up to 371 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLASSIA0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventGLASSIA
Platelet count decreased/Investigations1/1
PruritusSkin and subcutaneous tissue disorders1/1
HyperglycaemiaMetabolism and nutrition disorders1/1
HypocalcaemiaMetabolism and nutrition disorders1/1
Vision blurredEye disorders1/1
HypokalaemiaMetabolism and nutrition disorders1/1
Weight decreasedInvestigations1/1
Blood cholesterol increasedInvestigations1/1
HypomagnesaemiaMetabolism and nutrition disorders1/1
ArthralgiaMusculoskeletal and connective tissue disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GLASSIA
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)GLASSIA
Female0
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GLASSIA
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GLASSIA
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Georgia Cancer Center
    Augusta, Georgia 30912, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the low number of study participants).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2018, 12 months.

Results were first posted in Apr 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2016
First posted
Nov 6, 2016
StartActual
Apr 26, 2017
Primary completionActual
May 3, 2018
CompletionActual
May 3, 2018
Results first posted
Apr 24, 2019
Last update
Jan 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02956122
Collaborators
Kamada, Ltd.
Responsible party
Sponsor
First posted
Nov 6, 2016
Start date
Apr 26, 2017
Primary completion
May 3, 2018
Completion
May 3, 2018
Results posted
Apr 24, 2019
Last update
Jan 13, 2021

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion